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We demonstrated the presence of two adeno-associated viruses (AAVs), designated AAV10 and AAV11, in cynomolgus monkeys by
isolating and sequencing the entire viral coding regions from the monkey DNA. AAV10 and AAV11 capsid proteins shared 84% and 65%,
respectively, of amino acids with AAV2. A phylogenetic analysis of AAV capsid proteins showed that AAV10 and AAV11 resembled most
AAV8 and AAV4, respectively. To characterize the capsid protein, we pseudotyped an AAV2 vector with the monkey AAV capsid proteins
and examined the resulting pseudotypes AAV2/10 and AAV2/11, in comparison with the AAV2 vector, for their host ranges in cell lines and
tissue tropism in mice. AAV2/10 and AAV2/11 transduced primate cells less efficiently than AAV2. Whereas AAV2 transduced
undifferentiated C2C12 mouse myoblasts more efficiently than differentiated ones, AAV2/10 and AAV2/11 transduced the undifferentiated
myoblasts less efficiently than differentiated ones. Three weeks after injection to the muscle of the hind legs, AAV2/10 and AAV2 induced
transgene expression similarly, but AAV2/11 did not transduce the skeletal muscle. Six weeks after systemic administration, transduced
vector DNAwas detected by PCR in the liver and spleen of mice inoculated with AAV2, in the liver, heart, muscle, lung, kidney, and uterus
of mice with AAV2/10, and the muscle, kidney, spleen, lung, heart, and stomach of mice with AAV2/11. Mouse antisera against capsid
protein VP2 of the three AAVs neutralized the respective vector particles in a type-specific manner. The results indicate that AAV10 and
AAV11 capsid proteins, which are antigenically distinct from each other and AAV2, are likely to determine their host ranges and tissue
tropism that are different from AAV2s, suggesting that cynomolgus AAVs could provide a broader choice of pseudotype AAV vectors for
gene therapy.
D 2004 Elsevier Inc. All rights reserved.
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Adeno-associated virus (AAV), a nonenveloped small
DNAvirus, belongs to the genus Dependovirus of the family
Parvoviridae and usually requires coinfection with a helper
virus such as adenovirus for its replication (Muzyczka and
Berns, 2001). Among eight primate AAV serotypes known0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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studied for its genomic structure and gene functions. The
genome, 4.7 kb single-stranded linear DNA, has two large
open reading frames (ORFs); the left ORF encoding the
nonstructural Rep proteins and the right ORF, the capsid
proteins VP1, VP2, and VP3. At each end of the genome is a
145 base region (inverted terminal repeat, ITR) containing
the viral origin of DNA replication and the packaging signal
(Muzyczka and Berns, 2001). Upon infection, AAV2 was
believed to specifically integrate its genome into human
chromosome 19; thus, it has been studied for its potential
use as a gene-transfer vector in gene therapy.
Pseudotyping the AAV2 vector with capsids from
AAVs other than AAV2 has been conducted to address04) 375–383
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range and antigenicity (both determined by the capsid)
(Rabinowitz et al., 2002). Development of pseudotyped
vectors would require more information on AAVs and
preferably more new isolates. AAV1, 2, 3, 4, and 6 were
initially found as contaminants in laboratory adenovirus
stocks (Atchison et al., 1965; Hoggan and Blacklow,
1966; Melnick et al., 1965). The natural host of AAV1 is
unclear at present. AAV2 and AAV3 were later isolated
from human infants. AAV4 was isolated from a culture of
a rhesus monkey kidney. AAV5 was isolated from a
human penile condylomatous wart (Bantel-Schaal and zur
Hausen, 1984; Georg-Fries et al., 1984). AAV6 appears to
be a recombinant between AAV1 and AAV2 (Xiao et al.,
1999). AAV7, AAV8, and AAV9 have been recently
found in rhesus monkeys (Gao et al., 2002, 2004). A
recent study suggests that many AAVs as yet to be
identified are widely disseminated throughout multiple
tissues of nonhuman primate species (Gao et al., 2003,
2004).
In this study, we isolated and sequenced coding regions
of two novel AAV sequences, AAV10 and AAV11, from
the tissues of cynomolgus monkeys. We pseudotyped an
AAV vector, using capsids of these AAVs, and compared
the resulting vectors with the AAV2 vector for their
infectivity on cultured cell lines, transduction efficiencies
in the mouse skeletal muscle, and organ tropism in mice.
We prepared mouse antisera against VP2 of three AAVs
and examined them for their cross-neutralization of the
three vectors and vectors of AAV4 and AAV8, of which
amino acid sequences resembled those of AAV10 and
AAV11, respectively.Results
Isolation of DNA fragments encoding cap genes of AAV10
and AAV11
The alignment of the genomes of known eight types of
AAV shows that several regions have common nucleotide
sequences. The common sequences were used to design the
consensus primers, CP1 to CP5 (Fig. 1A), for PCR to
amplify unidentified AAV genomes putatively contained in
DNA samples that were extracted from five cynomolgus
monkeys. CP1 and CP2 are primers to amplify the
bsignature regions (Gao et al., 2002)Q, of which nucleotide
sequences are highly type specific.
Two novel AAV bsignature regionsQ were found in the
DNA samples extracted from liver (animals #1, #4, and #5)
and heart (#5). The DNA fragments amplified by PCR were
cloned and sequenced. The nucleotide sequences of the
clones did not agree with those of the signature regions of
the known AAVs, indicating that they were derived from
two novel AAVs; thus designated AAV 10 and AAV11. The
sequence of AAV10 was found in DNA samples extractedfrom the livers of #1, #4, and #5 and the heart of #5. The
sequence of AAV11 was found in DNA samples extracted
from the livers of #1 and #5.
The entire coding region of AAV10 was obtained by three
sets of PCR (Fig. 1A). The DNA sample extracted from the
intestine of #4, which contained relatively abundant copies
of AAV10 bsignature regionQ, was used for the template to
amplify the coding region of AAV10 DNA. The DNA
fragment (10-A) was obtained by using CP3 and SP1 that
were complementary to the central region of the AAV10
bsignature regionQ. Based on the nucleotide sequences of 10-
A, two AAV10-specific primers (SP2 and SP3) were
designed. The 5V region of the coding region (10-B) was
obtained by using SP2 and CP4 and the 3V region of the
coding region (10-C) was obtained by using SP3 and CP5.
The nucleotide sequences of 3V region of 10-B were identical
with those of 5V region of 10-A and the nucleotide sequences
of 3V region of 10-Awere identical with those of 5V region of
10-C. 10-A and 10-C were connected at Bsu36I site (Fig.
1A), and the resultant DNA fragment was used to generate
AAV2/10 (GenBank accession number for AAV10:
AY631965).
The entire coding region of AAV11 was obtained by two
sets of PCR using the DNA sample extracted from the liver
of #5 (Fig. 1A). The 5V region of the coding region (11-A)
was amplified by using CP4 and SP4 that were comple-
mentary to the central region of the AAV11 bsignature
regionQ. The 3V region of the coding region (11-B) was
obtained by using CP3 and CP5. The nucleotide sequences
of 3V region of 11-Awere identical with those of 5V region of
11-B (GenBank accession number for AAV11:AY631966).
The amino acid sequences of capsid protein of AAV10
and AAV11 were deduced from the nucleotide sequences
(Fig. 1B). AAV10 and AAV11 capsid proteins shared 84%
and 65%, respectively, of amino acids with AAV2.
Phylogenetic analysis showed that AAV10 and AAV11 were
closely related to AAV8 and AAV4, respectively (Fig. 1C).
Production of pseudotype vectors AAV2/10 and AAV2/11
Pseudotype AAV vectors AAV2/10 and AAV2/11 were
generated by the cross-packagings of the AAV2 vector
genome expressing a reporter gene, the h-galactosidase (h-
gal) gene or a gene encoding the enhanced green
fluorescence protein (EGFP) fused with alpha-tubulin, into
capsids of AAV10 and AAV11. The helper/packaging
plasmids for AAV2/10 and AAV2/11 were constructed by
replacement of the 3V region of AAV2 genome with those
of AAV10 or AAV11 genome (Fig. 2). The pseudotyped
vectors were purified by CsCl-equilibrium density gradient
centrifugation. The density of AAV2/11 particles was
slightly higher than those of the AAV2 vector and
AAV2/10 particles. Although the AAV2 vector bound to
heparin-agarose as previously reported, AAV2/10 and
AAV2/11 did not bind. AAV2/10 and AAV2/11 bound to
anion-exchange resin in a buffer with 0.1 M NaCl. AAV2/
Fig. 1. Strategy for isolation and characterization of cap genes of AAV10 and 11. (A) Primers used for amplification of cap genes. CP1 to CP5 are consensus
primers annealing to regions having common nucleotide sequences among genomes of known eight AAV serotypes. SP1 to SP3 and SP4 are AAV10- and
AAV11-specific primers. SR indicates the bsignature regionQ of AAV cap gene described by Gao et al. (2002). (B) Amino acid sequences of cap genes. The
predicted amino acid sequences of the capsid proteins are aligned for AAV2, AAV4, and AAV8. Amino acid identities with AAV2 sequences are indicated by
(:) and gaps are indicated by (). (C) Phylogenetic analysis of amino acid sequences of the capsid proteins. Phylogenetic tree was implemented with
CLUSTAL W.
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and AAV2/11 was eluted with 0.6 M NaCl. The data
indicate the biochemical natures of these capsids are
different.
Transduction of cultured cells with the pseudotyped vectors
AAV2/10 and AAV2/11 were capable of transducing
various human and monkey cells. Among the conventionalcell cultures tested, except for HeLa and A172 cells,
transduction efficiencies with AAV2/10 and AAV2/11
were approximately 1/100 of those with the AAV2 vector
(Fig. 3A). The transduction efficiencies of HeLa and A172
with AAV2/11 were extremely low (Fig. 3A). Addition of
mucine to inocula of the vectors did not reduce their
transduction efficiency, indicating that AAV2/10 and
AAV2/11 did not require sialic acid for efficient infection
(Walters et al., 2002).
Fig. 2. Schematic representation of the helper and packaging plasmids used for producing the pseudotyped vectors. The helper/packaging plasmid for the
production of AAV2 vector was constructed by subcloning of E2a, E4, and VA genes of adenovirus type 5, rep and cap genes, and polyadenylation signal of
AAV2 into pSP72 (Promega). To enhance the efficiency of vector production, the first ATG of rep gene was mutated to ACG (Xiao et al., 1998). To produce
AAV2/10 and AAV2/11 pseudotype vectors, the entire cap and 3V end of rep genes of AAV2 were replaced with those of AAV10 and AAV11, respectively. The
BstpI or SalI sites of the AAV2 rep gene was used for the replacement of AAV2 sequence with AAV10 and AAV11 sequence, respectively. The polyA signal of
SV40, indicated as SV40pA, was located downstream of the cap gene.
Fig. 3. Transduction efficiency of AAV2 and the pseudotyped vectors. Cells
were inoculated with the serially diluted vectors capable of expressing h-
galactosidase (h-gal). Two days later, cells positive for h-gal were counted.
Each bar represents the average of three separate inoculations, with the
standard deviation indicated by an error bar. (A) Cells cultured with the
conventional method. (B) C2C12 mouse myoblasts were cultured in
Dulbecco’s modified minimal essential medium (DMEM) supplemented
with 10% fetal bovine serum as undifferentiated cells. When cells became
confluent, the medium was changed into DMEM with 2% horse serum and
maintained for 10 days to obtain differentiated cells.
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undifferentiated state when cultured in medium containing
10% fetal bovine serum (FBS). When the confluent culture
of the cells is maintained in medium containing 2% horse
serum for several days, the cells differentiate (Blau et al.,
1983). The AAV2 vector transduced the undifferentiated
C2C12 cells more efficiently than the differentiated C2C12
(Fig. 3B). AAV2/10 transduced the undifferentiated cells
only marginally but transduced the differentiated cells more
efficiently than the AAV2 vector (Fig. 3B). AAV2/11 did
not transduce the undifferentiated cells but transduced the
differentiated cells as efficiently as the AAV2 vector did
(Fig. 3B).
Injection of the vectors into the hind leg muscle of BALB/c
mice
The result of the transduction of C2C12 led us to
examine the transduction efficiencies of the skeletal muscle
with the pseudotyped vectors. The AAV vectors capable of
expressing h-gal (5  108 genome copies) were injected
into the tibialis anterior of 4-week-old BALB/c mice. Three
weeks later, the levels of h-gal were measured (Fig. 4).
Extracts from the muscles injected with AAV2/10 showed
h-gal activities comparable to that shown with the AAV2
vector. AAV2/11 did not transduced the skeletal muscle.
Systemic administration of the vectors to BALB/c mice
Tissue distribution of the vector genome significantly
varied with the vector in mice systematically administrated
with the AAV2 vector, AAV2/10, and AAV2/11. BALB/c
mice were injected with the vectors (109 genome copies per
animal) via tail vein. One and six weeks later, the tissues
were harvested and analyzed for the presence of vector
genomes by semi-quantitative PCR. Fig. 5 shows the
Fig. 4. Transduction of mouse skeletal muscle injected with AAV2, AAV2/
10, and AAV2/11 vectors capable of expressing h-galactosidase. AAV
vectors of 5  108 genome copies or physiological saline (for a mock-
inocula) was injected into the tibialis anterior of 4-week-old BALB/c mice
(three animals: six legs). Three weeks after the injection, the h-gal activities
were measured.
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the tissues.
In mice injected with the AAV2 vector, the vector
genomes were found in the liver, spleen, kidney, and muscle
at 1 week. At 6 weeks, the vector genomes in the kidney
and muscle disappeared and the genomes were mainly
present in the liver and spleen. Low levels of the genome
were found in the lung, muscle, and heart. In mice injected
with AAV2/10, the vector genomes were found in all the
tissues examined at 1 week. At 6 weeks, the genomes were
found in the liver, heart, muscle, lung, kidney, and uterus. InFig. 5. Distribution of AAV vector genomes in murine tissues. BALB/c mice were
gene via tail vein. One and six weeks later, mice were sacrificed and the tissues w
genomes in the DNA samples were amplified by semi-quantitative PCR using prim
gel electrophoresis. G3PDH gene was amplified for references. Results obtainedmice injected with AAV2/11, the vector genomes were
found in all the tissues examined at 1 week. At 6 weeks, the
genomes were found in the muscle, kidney, spleen, lung,
heart, and stomach. Noteworthy is that the genome in the
liver was marginal.
Neutralization of the pseudotyped vectors with antibodies
against VP2 of AAV2, AAV10, and AAV11
Mouse anti-AAV2, AAV10, and AAV11 were raised by
immunizing BALB/c mice with purified VP2 of AAV2,
AAV10, and AAV11. The amino acid sequence of VP2
includes the entire VP3 (the major capsid protein) sequence
and the great majority of VP1 sequence. Since amino acid
sequences of VP2s of AAV10 and AAV11 resemble those of
AAV8 and AAV4, respectively (Fig. 1C), similarly pro-
duced AAV2/8 (Gao et al., 2004) and AAV2/4 (Rabinowitz
et al., 2002) were included in neutralization tests. Neutraliz-
ing activities of the antisera were examined by testing the
ability to inhibit transduction of COS-1 cells by these
vectors. Anti-AAV2 and anti-AAV10 showed type-specific
neutralization. Anti-AAV11 did not neutralized AAV2 and
AAV10 but showed low level of cross-neutralizing activities
for AAV4.Discussion
Previously described bsignature regions (Gao et al.,
2002)Q, which have highly type-specific nucleotide sequen-
ces and are flanked by nucleotide sequences common to theinoculated with vectors having enhanced green fluorescence protein (EGFP)
ere harvested. Genomic DNAwas isolated from tissues indicated and AAV
ers for EGFP gene. The amplified DNA fragment was analyzed by agarose
by two animals were very similar.
Table 1
Cross reactivity of anti-VP2 antisera
Antiserum Vector
AAV2 AAV2/4 AAV2/8 AAV2/10 AAV2/11
AAV2 160 b10 b10 b10 b10
AAV10 b10 b10 40 2560 10
AAV11 b10 160 b10 b10 2560
Antibody titer was presented as the reciprocal of the highest dilution that
repressed number of h-gal positive cells to half of the number obtained with
the sample mixed with the similarly diluted serum from nonimmunized
mice.
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AAV sequences in cynomolgus monkeys. By amplifying the
signature regions, we found two novel AAV sequences,
designated AAV10 and AAV11, using the DNA samples
obtained from five adult monkeys; two had AAV10, two had
both AAV10 and AAV11, and one had neither AAV10 nor
AAV11. From the available records on breeding and
maintenance of the monkeys, it was not clear how the
animals had been infected with these AAVs.
Sequencing the cloned viral coding regions, particularly
the capsid gene, revealed the similarity and difference
between AAV2 and the cynomolgus AAVs, which turned
out to resemble most of the rhesus AAVs (Fig. 1). Capsids
play important roles in several steps of infection; binding
with a cellular receptor, trafficking to the nucleus, and
uncoating. Capsid is also the target of neutralizing anti-
bodies. It is interesting to know whether the structural
difference of capsid protein affects the functions of a capsid.
To characterize AAV10 and AAV11 capsid proteins, we
pseudotyped the AAV2 vector with the cynomolgus AAV
capsids (Fig. 2) and compared the resulting pseudotyped
vectors AAV2/10 and AAV2/11 with the AAV2 vector for
their biological functions (Figs. 3–5). Studies of such
pseudotyped AAV2 vectors having capsids of AAV1 and
3–8 show that they have tissue tropism different from that of
the AAV2 vector and that they are not neutralized by anti-
AAV2 sera (Grimm and Kay, 2003).
In this study, newly produced pseudotypes AAV2/10 and
AAV2/11 showed that their tissue tropism is different from
and apparently broader than that of the AAV2 vector in
mice. AAV2/10 transduced the differentiated C2C12, a
mouse myoblast line, more efficiently than undifferentiated
C2C12, although the AAV2 vector transduced differentiated
C2C12 much less efficiently than undifferentiated C2C12
(Fig. 3). Similarly, AAV2/11 transduced the differentiated
cells more efficiently than undifferentiated cells, although
the level of the transduction was low (Fig. 3). Probably, the
capabilities of AAV2/10 and AAV2/11 to transduce the
differentiated C2C12 are related with the expression of the
transgene in the skeletal muscle injected with AAV2/10 and
AAV2/11 (Fig. 4). The tropism to the muscle was also
observed with AAV2/10 and AAV2/11 after systemic
administration of vectors (Fig. 5). Previous studies indicate
that the pseudotyped AAV2 vectors having capsids of
AAV1, AAV5, and AAV7 transduce the mouse skeletal
muscle more efficiently than the AAV2 vector (Chao et al.,
2000; Duan et al., 2001; Gao et al., 2002; Hildinger et al.,
2001).
The mouse antibodies against AAV2, AAV10, and
AAV11 were not cross-neutralizing one another (Table 1).
This finding indicates that AAV2/10 and AAV2/11 appa-
rently have the advantage of not being neutralized with the
antibody against AAV2 when used as a gene-transfer vector
for humans. Although capsid amino acid sequences of
AAV10 and AAV11 resemble those of AAV8 and AAV4,
respectively, anti-AAV10 did not cross-neutralized AAV8(1:40 in Table 1) and anti-AAV11 showed a very low level
of cross-neutralization for AAV4 (1:160 in Table 1).
These results, taken together with their characteristic
tissue tropism, suggest that AAV10 and AAV11 could
provide a broader choice of pseudotyped AAV vectors for
trials of gene therapy.Materials and methods
Animals and tissues
Tissues of cynomolgus macaques were obtained from the
Tsukuba Primate Center for Medical Science, National
Institute of Infectious Diseases. BALB/c mice were pur-
chased from Nihon SLC Co. Ltd. (Shizuoka, Japan). All
animal studies were performed in accordance with the
guidelines of the National Institute of Infectious Diseases.
Cells
HEK293 (human embryonic kidney cells transformed by
adenovirus type 5), HeLa (human cervical cancer cells),
Alexander (human hepatoma cells), C2C12 cells (mouse
myoblast), COS-1 (CV1 cells positive for SV40 T), and
A172 (human glioblastoma) were maintained in Dulbecco’s
modified minimal essential medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and cultured in 5% CO2
at 37 8C. Sf9 insect cells were grown in SFM medium
supplemented with 3% FBS at 27 8C.
Extraction of DNA from tissues
Animal tissues were harvested at necropsy and stored at
80 8C until use. DNA was extracted from approximately
25 mg of each frozen tissue by using QIAamp DNA
extraction kit (Qiagen GmbH, Hilden, Germany).
PCR to amplify DNA fragments of AAV10 and AAV11
The consensus primers CP1 and CP2 used for amplifica-
tion of the bsignature regionQ of AAV cap gene were
described by Gao et al. (2002). Other consensus primers
used in this study were the following: CP3, 5V-
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AACGAGCAGCAGCCATG; CP5, 5V-CGCAGAGACCA-
AAGTTCAACTGAAACGA. AAV10-specific primers were
the following: SP1, 5V-GTGATGACTCTGTCGCCCAG;
SP2, 5V-AGGACTTGCACTTTTGGTCG; SP3, 5V-ATGGC-
TGCAGGCGGTGGCGCT. AAV11-specific primer SP4
was 5V-TGGTTGTTGTAGGTGGGCAAGA.
PCR consisted of the initial heating at 94 8C for 5 min,
40 cycles of incubation at 94 8C for 30 s plus at 68 8C for 2
or 5 min, and the final incubation at 68 8C for 7 min. PCR
products were purified by gel filtration and cloned into
pGEM-T Easy vector (Promega corporation, Madison, WI).
Nucleotide sequence was analyzed with an ABI-PRISM 310
sequencer (PE Applied Biosystems, Foster City, CA).
Consensus sequences of at least five clones obtained by
independent PCR amplifications were selected as the
sequences of AAV10 and 11.
Production and purification of pseudotyped AAV vectors
AAV vectors were produced by cotransfection of vector
plasmid (pAAVh-gal or pAAVEGFPtub) and helper/pack-
aging plasmid (pEEV2 for AAV2 vector, pEEV2/10 for
pseudotyped AAV10 vector, pEEV2/11 for pseudotyped
AAV11 vector, pEEV2/4 for pseudotyped AAV4 vector,
and pEEV2/8 for pseudotyped AAV8 vector). pAAVh-gal
had a DNA region composed of the inverted terminal
repeats (ITR) of AAV2, the expression unit composed of
cytomegalovirus immediate early promoter, h-gal gene, and
another ITR. pAAVEGFPtub had a DNA region composed
of ITR, the human elongation factor I alpha promoter, a
fusion gene of enhanced green fluorescence protein gene
and alpha-tubulin gene, and another ITR. pEEV2 was
constructed by subcloning of E2a, E4, and VA genes of
adenovirus and rep and cap genes and polyadenylation
signal of AAV2 into pSP72 (Promega). pEEV2/10 had a 2/
10-chimeric rep gene (5V end to the BstPI site of AAV2 rep
gene plus the BstPI site to 3V end of AAV10 rep gene),
AAV10 cap gene, and SV40 polyadenylation signal.
pEEV2/11 had a 2/11-chimeric rep gene (5V end to the
SalI site of AAV2 rep gene plus the SalI site to 3V end of
AAV11 rep gene), AAV11 cap gene, and the SV40 poly-
adenylation signal. pEEV2/4 had a 2/4-chimeric rep gene
(5V end to the SalI site of AAV2 rep gene plus the SalI site
to 3V end of AAV4 rep gene), AAV4 cap gene, and the
SV40 poly-adenylation signal. The AAV4 region was
obtained from AAV4 DNA (ATCC No. VR-646). pEEV2/
8, which had AAV2 rep gene and AAV8 cap gene and
polyadenylation signal, was constructed from pAAV2/8
(Gao et al., 2002).
Subconfluent cultures of HEK293 cells in 15-cm dish (10
dishes) were transfected with a mixture of 250 mg of vector
plasmid and 250 mg of helper/packaging plasmid by the
calcium phosphate coprecipitation method. Three days later,
the cells were collected by a low-speed centrifugation and
resuspended with phosphate-buffered saline (PBS) contain-ing 10 mM MgCl2. The suspension was frozen and thawed
three times, followed by a brief sonication, and centrifuged at
3000 rpm for 15 min at 4 8C. The supernatant was incubated
with Benzonase (50 U/ml) for 30 min at 37 8C, then mixed
with CsCl to a final density of 1.41 g/ml, and centrifuged in a
SW50.1 swinging bucket rotor (Beckman Coulter Inc.,
Fulleron, CA) at 36000 rpm for 42 h at 20 8C. Fractions
containing the vectors were collected, dialyzed against PBS
or physiological saline at 4 8C to remove CsCl, and stored at
4 8C as a vector stock. Genome copy numbers of the vector
stocks were measured by real-time PCR using TaqMan
probes (Perkin-Elmer Biosystems, Foster City, CA).
Transduction of cultured cells with the AAV vectors
Cells, except for C2C12 cells, were seeded in 48-well
plates at a density of 1  104 cells/well. Next day, cells were
inoculated with AAV vectors diluted serially (from 2  108
to 2  104 genome copies). Cells were incubated for 2 h
with occasional locking at 37 8C, and then fresh medium
was added to each well. Two days after the inoculation, the
cells were fixed and stained for h-gal expression by In Situ
h-Galactosidase Staining Kit (Stratagene, La Jolla, CA).
The cells positive for h-gal were counted under light
microscopy.
In the case of C2C12 cells, undifferentiated cells (2 
104 cells/well) and differentiated cells (confluent cells were
cultured in DMEM containing 2% horse serum for 10 days)
in 48-well plate were inoculated with AAV vectors diluted
serially (from 2  108 to 2  104 genome copies). Three
days after inoculation, h-gal-positive cells were counted
similarly.
Transduction of the skeletal muscle with the AAV vectors
For muscle-directed transduction, 5  108 genome
copies of AAV vectors having h-gal gene were injected
into the tibialis anterior of 4-week-old BALB/c mice.
Three weeks after injection, mice were sacrificed and
lower legs were collected. The lower leg was homogenized
in 500 Al of lysis buffer (0.25 M Tris pH 8.0) by Mixer
Mill MM300 (Qiagen) at 25 Hz for 2 min. After
centrifugation at 12000 rpm for 5 min at 4 8C, 30 Al of
the supernatant was used to measure h-gal activity by
using h-Gal Assay kit (Invitrogen) according to the
manufacture’s protocol. Briefly, the sample was mixed
with 200 Al of cleavage buffer and 70 Al of o-Nitrophenyl-
h-d-Galactopyranoside and incubated at 37 8C for 16 h.
To stop the reaction, 500 Al of stop buffer was added, and
the absorbance of the reaction mixture was measured at
414 nm.
Tissue distribution of the AAV vectors in mice
Eight-week-old female BALB/c mice (four animals per
group) were injected with the AAV vectors (1  109 genome
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1 and 6 weeks after injection, two animals in a group were
sacrificed. At necropsy, organs were collected, frozen
immediately in a dry ice, and stored at 80 8C. DNA
(500 ng) was extracted from the organ and used for the
template of PCR to amplify EGFP gene with primers (the
forward primer: 5V-TTCATCTGCACCACCGGCAA, the
reverse primer: 5V-CCGTCCTCCTTGAAGTCGAT). For
the internal control, the G3PDH gene was amplified by
using the primer set described previously (Mori et al.,
2002). PCR consisted of the initial heating at 94 8C for 5
min, 34 cycles (for amplification of EGFP gene) or 20
cycles (for amplification of G3PDH gene) of incubation at
94 8C for 30 s plus at 68 8C for 1 min, and incubation at
68 8C for 5 min.
Production of antiserum against VP2 of AAV2, AAV10, and
AAV11
The VP2 protein was expressed in insect Sf9 cells by
using recombinant baculovirus system (Bac system, Invi-
trogen). The VP2 coding region was inserted downstream of
the polyhedrin promoter of plasmid pFastBac1 (Invitrogen).
The plasmid was introduced into Escherichia coli
DH10Bac-competent cells (Invitrogen) that contain Bacmid
DNA and the helper plasmid to obtain recombinant Bacmid
DNA. The recombinant baculovirus was produced in Sf9
cells transfected with the recombinant Bacimid DNA. For
large-scale expression of VP2 protein, Sf9 cells (five bottles
of 175-cm2 culture flask) were infected with the recombi-
nant baculovirus at multiplicity of infection (MOI) of 10 and
incubated for 4 days at 27 8C. The cells were collected and
suspended in 5 ml PBS containing 0.5% NP-40. After
incubation on ice for 15 min, the cells were centrifuged at
10000  g for 15 min at 4 8C to precipitate nuclei. The
nuclei were washed with PBS containing 0.5% NP-40,
resuspended with 2 ml PBS containing the protease inhibitor
cocktail (Roche Diagnostics Co. Ltd., Mannheim, Ger-
many), and lysed with brief sonication. The lysate was
layered onto sucrose cushions of 30% and 5% sucrose (wt/
vol) in PBS and centrifuged at 120000  g for 2.5 h at 4 8C
in a SW50.1 rotor (Beckman Coulter Inc.). The precipitate,
which contained majority of VP2, was resuspended in PBS
containing CsCl (1.32 g/ml) and the protease inhibitor
cocktail (Roche Diagnostics Co. Ltd.) and lysed with brief
sonication. The lysate was centrifuged at 35000 rpm for 20
h at 20 8C with an SW50.1 rotor (Beckman Coulter Inc.).
The fractions with a visible protein band was collected and
dialyzed against physiological saline at 4 8C to remove
CsCl.
Eight-week-old female BALB/c mice (five animals) were
immunized with VP2 protein (20 Ag/animal) emulsified
with TiterMax Gold (TiterMax USA INC., Norcross, GA)
twice at an interval of 2 weeks subcutaneously. At 2 weeks
after the second immunization, mice were boosted with 5 Ag
of VP2 protein by intravenous injection. Serum wascollected from five animals at 4 days after the booster
injection and pooled.
Neutralizing activity of antiserum
Neutralizing activities of the mouse anti-VP2 serum
were measured by testing inhibition of transduction of
COS-1 cells by the AAV vectors expressing h-gal. COS-1
cells (1  105 cells/well) were seeded in 24-well plate 1 day
before inoculation. One hundred and ten microliters of
vector solution (2  103 transducing unit/ml) was mixed
with 110 Al of the serum that had been serially diluted from
1:10 to 1:40960 with PBS and incubated for 1 h at 37 8C.
Then, the sample was mixed with 200 Al of DMEM
containing 10% FBS and inoculated to the cells in two
wells (200 Al/well). After incubation with occasional
locking for 2 h at 37 8C, 500 Al of fresh DMEM containing
10% FBS was added to each well. Two days later, cells
positive for h-gal were detected as described above.
Neutralizing titer of the antiserum was expressed as the
reciprocal of the highest dilution that repressed number of
h-gal positive cells to half of the number obtained with the
samples mixed with the similarly diluted serum from
nonimmunized mouse.Acknowledgments
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